# A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)

> **NCT04624659** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Forma Therapeutics, Inc.** · enrollment: 450 (estimated)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Etavopivat Tablets Low dose
- **DRUG:** Etavopivat Tablets High dose
- **DRUG:** Placebo Tablets
- **DRUG:** Etavopivat Tablets

## Key facts

- **NCT ID:** NCT04624659
- **Lead sponsor:** Forma Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-01-29
- **Primary completion:** 2026-02-06
- **Final completion:** 2027-03-19
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04624659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04624659, "A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04624659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*